267 related articles for article (PubMed ID: 28923878)
21. Identification and antimicrobial susceptibility of clinical Nocardia species in a tertiary hospital in China.
Wei M; Wang P; Qu J; Li R; Liu Y; Gu L; Yang C
J Glob Antimicrob Resist; 2017 Dec; 11():183-187. PubMed ID: 28870771
[TBL] [Abstract][Full Text] [Related]
22. Multicenter study in Taiwan of the in vitro activities of nemonoxacin, tigecycline, doripenem, and other antimicrobial agents against clinical isolates of various Nocardia species.
Lai CC; Liu WL; Ko WC; Chen YH; Tan HR; Huang YT; Hsueh PR
Antimicrob Agents Chemother; 2011 May; 55(5):2084-91. PubMed ID: 21343461
[TBL] [Abstract][Full Text] [Related]
23. In vitro activity of tedizolid and comparator agents against Gram-positive pathogens responsible for bone and joint infections.
Ract P; Piau-Couapel C; Compain F; Auzou M; Michon J; Cattoir V
J Med Microbiol; 2017 Oct; 66(10):1374-1378. PubMed ID: 28920854
[TBL] [Abstract][Full Text] [Related]
24. In vitro activities of linezolid against multiple Nocardia species.
Brown-Elliott BA; Ward SC; Crist CJ; Mann LB; Wilson RW; Wallace RJ
Antimicrob Agents Chemother; 2001 Apr; 45(4):1295-7. PubMed ID: 11257051
[TBL] [Abstract][Full Text] [Related]
25. Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens.
Zhanel GG; Love R; Adam H; Golden A; Zelenitsky S; Schweizer F; Gorityala B; Lagacé-Wiens PR; Rubinstein E; Walkty A; Gin AS; Gilmour M; Hoban DJ; Lynch JP; Karlowsky JA
Drugs; 2015 Feb; 75(3):253-70. PubMed ID: 25673021
[TBL] [Abstract][Full Text] [Related]
26. Comparative in vitro activities of nemonoxacin, doripenem, tigecycline and 16 other antimicrobials against Nocardia brasiliensis, Nocardia asteroides and unusual Nocardia species.
Lai CC; Tan CK; Lin SH; Liao CH; Chou CH; Hsu HL; Huang YT; Hsueh PR
J Antimicrob Chemother; 2009 Jul; 64(1):73-8. PubMed ID: 19398458
[TBL] [Abstract][Full Text] [Related]
27. In vitro activity of fluoroquinolones against clinical isolates of Nocardia identified by partial 16S rRNA sequencing.
Hansen G; Swanzy S; Gupta R; Cookson B; Limaye AP
Eur J Clin Microbiol Infect Dis; 2008 Feb; 27(2):115-20. PubMed ID: 17992548
[TBL] [Abstract][Full Text] [Related]
28. Activity of linezolid and tedizolid against clinical isolates of methicillin-resistant and methicillin and linezolid resistant Staphylococcus aureus: an in vitro comparison.
Peñuelas M; Candel FJ; Lejarraga C; López-González L; Viñuela-Prieto JM; López de Mendoza D
Rev Esp Quimioter; 2016 Oct; 29(5):255-8. PubMed ID: 27374726
[TBL] [Abstract][Full Text] [Related]
29. Susceptibility of rapidly growing mycobacteria and Nocardia isolates from cats and dogs to pradofloxacin.
Govendir M; Norris JM; Hansen T; Wigney DI; Muscatello G; Trott DJ; Malik R
Vet Microbiol; 2011 Dec; 153(3-4):240-5. PubMed ID: 21726965
[TBL] [Abstract][Full Text] [Related]
30. Antimicrobial susceptibility profiles and species distribution of medically relevant Nocardia species: Results from a large tertiary laboratory in Australia.
Tan YE; Chen SC; Halliday CL
J Glob Antimicrob Resist; 2020 Mar; 20():110-117. PubMed ID: 31400449
[TBL] [Abstract][Full Text] [Related]
31. Epidemiology and susceptibility to antimicrobial agents of the main Nocardia species in Spain.
Valdezate S; Garrido N; Carrasco G; Medina-Pascual MJ; Villalón P; Navarro AM; Saéz-Nieto JA
J Antimicrob Chemother; 2017 Mar; 72(3):754-761. PubMed ID: 27999029
[TBL] [Abstract][Full Text] [Related]
32. In vitro activity of tedizolid against linezolid-resistant staphylococci and enterococci.
Silva-Del Toro SL; Greenwood-Quaintance KE; Patel R
Diagn Microbiol Infect Dis; 2016 May; 85(1):102-4. PubMed ID: 26971179
[TBL] [Abstract][Full Text] [Related]
33. [Antimicrobial susceptibilities of clinical Nocardia isolates identified by 16S rRNA gene sequence analysis].
Uner MC; Hasçelik G; Müştak HK
Mikrobiyol Bul; 2016 Jan; 50(1):11-20. PubMed ID: 27058325
[TBL] [Abstract][Full Text] [Related]
34. Identification and antimicrobial susceptibility of referred
Yeoh K; Globan M; Naimo P; Williamson DA; Lea K; Bond K
J Med Microbiol; 2022 Aug; 71(8):. PubMed ID: 35976092
[No Abstract] [Full Text] [Related]
35. Efficacy of tedizolid against methicillin-resistant Staphylococcus aureus and Peptostreptococcus anaerobius in thigh mixed-infection mouse model.
Yamagishi Y; Mikamo H; Kato H; Nishiyama N; Asai N; Koizumi Y; Sakanashi D; Suematsu H; Matsuura K; Hagihara M
J Infect Chemother; 2017 Jun; 23(6):368-373. PubMed ID: 28343752
[TBL] [Abstract][Full Text] [Related]
36. Use of Translational Pharmacokinetic/Pharmacodynamic Infection Models To Understand the Impact of Neutropenia on the Efficacy of Tedizolid Phosphate.
Xiao J; Gill C; Liang L; Liu J; Wu J; Feng HP; Flanagan S; Tan C; Flattery A
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30373794
[TBL] [Abstract][Full Text] [Related]
37. Activity of novel oxazolidinones against Nocardia brasiliensis growing within THP-1 macrophages.
Vera-Cabrera L; Espinoza-González NA; Welsh O; Ocampo-Candiani J; Castro-Garza J
J Antimicrob Chemother; 2009 Nov; 64(5):1013-7. PubMed ID: 19710075
[TBL] [Abstract][Full Text] [Related]
38. In vitro activity of PNU-100766 (linezolid), a new oxazolidinone antimicrobial, against Nocardia brasiliensis.
Vera-Cabrera L; Gómez-Flores A; Escalante-Fuentes WG; Welsh O
Antimicrob Agents Chemother; 2001 Dec; 45(12):3629-30. PubMed ID: 11709356
[TBL] [Abstract][Full Text] [Related]
39. MLSA phylogeny and antimicrobial susceptibility of clinical Nocardia isolates: a multicenter retrospective study in China.
Wei M; Xu X; Yang J; Wang P; Liu Y; Wang S; Yang C; Gu L
BMC Microbiol; 2021 Dec; 21(1):342. PubMed ID: 34903163
[TBL] [Abstract][Full Text] [Related]
40. Retrospective Analysis of Antimicrobial Susceptibility Profiles of
Hamdi AM; Fida M; Deml SM; Abu Saleh OM; Wengenack NL
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31818815
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
